Dr. Elena Hartwig
Chief Executive Officer
A fermentation process engineer by training, Elena spent two decades scaling microbial biologics before founding Tandemab. She still reviews every commercial campaign personally.
HOME / TEAM
Leadership
Operators who've shipped molecules.
Tandemab is led by people who have run fermenters at 3am, defended dossiers in front of regulators and carried programs all the way to market. Bench credibility, plant scars, no slideware.
Dr. Marcus Oyelaran
Chief Scientific Officer
Marcus leads strain development and the FoldForge platform. His work on protease-deficient hosts has unlocked dozens of "undruggable" microbial targets for partners.
Dr. Priya Venkat
SVP, Process Development
Priya owns the bridge from bench to plant. She built Tandemab's scale-down qualification methodology that keeps at-scale titers within tolerance of lab predictions.
Thomas Sandhaug
SVP, GMP Manufacturing
Thomas runs Tandemab's three sites. A 25-year manufacturing veteran, he has overseen more than forty regulatory inspections without a single critical finding.
Dr. Aiko Renmark
VP, Analytical Sciences
Aiko leads method development, characterization and release. She is a recognized voice on host-cell protein clearance and higher-order structure comparability.
Daniel Cortez
VP, Regulatory & Quality
Daniel has authored and defended CMC sections for biologics approved on three continents. He embeds regulatory strategy into programs from the first feasibility run.
Dr. Lena Möller
VP, Business Development
A former PhD microbiologist turned dealmaker, Lena translates partner science into scoped programs and is most clients' first technical conversation at Tandemab.
Talk to the people who'll run it
Your program, our bench.
When you engage Tandemab you talk to the scientists doing the work — not a relay of account managers.